We serve Chemical Name:3-[(4-Amino-3-methylphenyl)azo]benzenesulfonic acid CAS:55994-13-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![3-[(4-Amino-3-methylphenyl)azo]benzenesulfonic acid](https://a.dearchem.com/CAS2/55994-13-3.png)
Chemical Name:3-[(4-Amino-3-methylphenyl)azo]benzenesulfonic acid
CAS.NO:55994-13-3
Synonyms:m-((4-Amino-m-tolyl)azo)benzenesulphonic acid;3-[(4-AMINO-3-METHYLPHENYL)AZO]BENZENESULFONIC ACID;3-[(e)-(4-amino-3-methylphenyl)diazenyl]benzenesulfonic acid;EINECS 259-938-6
Molecular Formula:C13H13N3O3S
Molecular Weight:291.32600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.4 g/cm3
Index of Refraction:1.65
PSA:113.49000
Exact Mass:291.06800
LogP:4.90130
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like m-((4-Amino-m-tolyl)azo)benzenesulphonic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 259-938-6 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,m-((4-Amino-m-tolyl)azo)benzenesulphonic acid Use and application,3-[(e)-(4-amino-3-methylphenyl)diazenyl]benzenesulfonic acid technical grade,usp/ep/jp grade.
Related News: Besides McNamara’s hire, GSK said it’s expected to name a chair for the OTC firm later this year, who will then establish the board. (Z)-4-bromo-5- (bromomethylene)-3-butylfuran-2(5H)-one manufacturers Besides McNamara’s hire, GSK said it’s expected to name a chair for the OTC firm later this year, who will then establish the board. 3-(2-Hydroxypyridin-3-yl)benzaldehyde suppliers Expedite biocatalysis development by partnering with an API CDMO 3-benzyl-1,2,3-trimethylbenzo[e]indol-3-ium,bromide vendor & factory The review considered two cases of AML in patients treated with an investigational medicine, bb1111, in a clinical trial for sickle cell disease. Although there have been no reports of AML with Zynteglo, both medicines use the same viral vector and there was a concern that the vector may be implicated in the development of the cancer (insertional oncogenesis).,Although biocatalysis is globally acknowledged to be a valuable means of ensuring greener, more sustainable manufacturing, its implementation has reached stasis after increasing steadily for the past 10 – 15 years.
